Physician profile
Walter Dodard
NPI 1699720516
$1,384.09
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $239 · 2021: $319 · 2022: $249 · 2023: $139 · 2024: $26.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $621.60 | 2019-2023 | Lo Loestrin Fe |
| Minerva Surgical, INC | $154.17 | 2019 | |
| Pfizer INC. | $107.47 | 2022-2023 | |
| Ethicon US, LLC | $65.78 | 2019-2021 | |
| Axonics, INC. | $59.45 | 2020-2023 | Axonics, Bulkamid |
| Astellas Pharma US INC | $43.40 | 2022-2023 | Veozah, Myrbetriq |
| Caldera Medical, INC | $41.50 | 2022 | |
| Myovant Sciences INC. | $33.38 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.89 | 2022 | |
| Therapeuticsmd, INC. | $28.64 | 2021-2022 | |
| Glaxosmithkline, LLC. | $27.17 | 2021 | |
| Mimedx Group, INC. | $26.23 | 2024 | |
| Amag Pharmaceuticals, INC. | $22.44 | 2020 | |
| Sumitomo Pharma America, INC. | $20.78 | 2023 | Gemtesa |
| Exeltis, USA INC. | $20.55 | 2023 | Slynd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.70 | 2022 | |
| Davol INC. | $17.86 | 2019 | |
| Meditrina | $15.01 | 2021 | |
| Roche Diagnostics Corporation | $14.82 | 2019 | |
| Lupin INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Dodard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.